Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis..
Diabetes Obes Metab. 25(10), 3020-3029.
(2023).
(2022).
Fluid volume regulation in patients with heart failure..
Lancet Diabetes Endocrinol. 9(5), 257-258.
(2021). Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction..
N Engl J Med. 382(20), 1883-1893.
(2020). Hospitalisations for heart failure predict mortality in pulmonary hypertension related to congenital heart disease..
Heart. 105(6), 465-469.
(2019). Management of iron deficiency in chronic heart failure: Practical considerations for clinical use and future directions..
Eur J Intern Med. 65, 17-25.
(2019). A new vessel segmentation algorithm for robust blood flow quantification from two-dimensional phase-contrast magnetic resonance images..
Clin Physiol Funct Imaging. 39(5), 327-338.
(2019). Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry..
Eur J Heart Fail. 21(7), 921-929.
(2019).
(2019).
(2019). Association of Ambulatory Blood Pressure with All-Cause and Cardiovascular Mortality in Hemodialysis Patients: Effects of Heart Failure and Atrial Fibrillation..
J Am Soc Nephrol. 29(9), 2409-2417.
(2018). The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study..
J Cardiovasc Magn Reson. 20(1), 88.
(2018). Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application..
Cardiovasc Drugs Ther. 32(6), 617-624.
(2018).
(2018). Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study..
Am J Nephrol. 45(2), 136-145.
(2017). Iatrogenic Lutembacher Syndrome after Percutaneous Mitral Commissurotomy..
J Heart Valve Dis. 26(3), 368-371.
(2017). Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?.
Curr Vasc Pharmacol. 16(1), 30-43.
(2017). Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun..
Curr Pharm Des. 23(10), 1540-1550.
(2017). Restrictive Mitral Valve Annuloplasty: Prognostic Implications of Left Ventricular Forward Flow..
Ann Thorac Surg. 104(5), 1464-1470.
(2017). SPECT and PET in ischemic heart failure..
Heart Fail Rev. 22(2), 243-261.
(2017). Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker..
Cardiology. 134(3), 311-9.
(2016). Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure..
J Hypertens. 34(9), 1678-88.
(2016). Lipids, Statins and Heart Failure: An Update..
Curr Pharm Des. 22(31), 4796-4806.
(2016). Lone Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation..
Circulation. 134(15), 1068-1081.
(2016).
(2016).